Development of a core outcome set for disease modification trials in mild to moderate dementia: A systematic review, patient and public consultation and consensus recommendations
(2017)
Journal Article
Webster, L., Groskreutz, D., Grinbergs-Saull, A., Howard, R., O’Brien, J. T., Mountain, G., Banerjee, S., Woods, B., Perneczky, R., Lafortune, L., Roberts, C., McCleery, J., Pickett, J., Bunn, F., Challis, D., Charlesworth, G., Featherstone, K., Fox, C., Goodman, C., Jones, R., …Livingston, G. (2017). Development of a core outcome set for disease modification trials in mild to moderate dementia: A systematic review, patient and public consultation and consensus recommendations. Health Technology Assessment, 21(26), 1-192. https://doi.org/10.3310/hta21260
© Queen’s Printer and Controller of HMSO 2017. Background: There is currently no disease-modifying treatment available to halt or delay the progression of the disease pathology in dementia. An agreed core set of the best-available and most appropriat... Read More about Development of a core outcome set for disease modification trials in mild to moderate dementia: A systematic review, patient and public consultation and consensus recommendations.